Terumasa Hisano

Symptom presentation at diagnosis as a biological risk indicator in both resectable and unresectable pancreatic ductal adenocarcinoma

T Tomino, Keishi Sugimachi, Lingaku Lee, Takeshi Kurihara et autres

jp (code pays fourni par la source)

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study

M. Ueno, Kenji Ikezawa, Yoshito Komatsu, Hiroaki Nagano et autres

Background: Liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) improved survival outcomes of patients with treatment-naïve metastatic pancreatic adenocarcinoma (mPAC) compared with nab-paclitaxel + gemcitabine in the phase III NAPOLI-3 trial. However, no Japanese centre participated in NAPOLI-3. Therefore, this …

jp, fr (code pays fourni par la source)

Hypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer

Lingaku Lee, Masami Miki, Masayuki Hijioka, Terumasa Hisano et autres

Background: Cancer-associated thrombosis is a major complication in pancreatic cancer; however, its true burden and prognostic significance remain unclear, largely owing to under-detection of asymptomatic events. In addition, the clinical relevance of cancer-related hypercoagulability and neutrophil extracellular traps (NETs), which may link …

jp (code pays fourni par la source)

Clinical Implications of Polyploid Giant Cancer Cells in Solid Tumors: Biology, Diagnosis, and Therapeutic Considerations

Hiroshi Imaoka, Masafumi Ikeda, Masashi Wakabayashi, Kumiko Umemoto et autres

Polyploid giant cancer cells (PGCCs) are characterized by abnormal enlargement and considerable polyploidy. Though the presence of giant cancer cells has been documented for decades, they remain not fully understood, especially in clinical practice, due to diagnostic challenges, and confusion regarding synonyms …

jp (code pays fourni par la source)

Adjuvant S-1 Plus Metformin after Pancreatic Cancer Resection: A Multicenter Randomized Phase II Trial

Masayuki Furukawa, Masato Narita, Ichiro Sakamoto, Yutaka Itoh et autres

jp (code pays fourni par la source)

Understanding Polyploid Giant Cancer Cells: From Molecular Mechanisms to Clinical Implications

Hiroshi Imaoka, Masafumi Ikeda, Masashi Wakabayashi, Kumiko Umemoto et autres

Polyploid giant cancer cells (PGCCs) are characterized by abnormal enlargement and considerable polyploidy. Though the presence of giant cancer cells has been documented for decades, they remain not fully understood, especially in clinical practice, due to diagnostic challenges, and confusion regarding synonyms …

jp, ca (code pays fourni par la source)

Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis

Lingaku Lee, Yuichi Tachibana, Susumu Matsuo, Yusuke Niina et autres

PURPOSE Germline BRCA (g BRCA ) mutations confer increased sensitivity to platinum-based chemotherapy and have been associated with improved survival across several malignancies. This study investigated the effect of g BRCA mutation status on the antitumor activity of modified fluorouracil, folinic acid, …

jp (code pays fourni par la source)

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

BACKGROUND: Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the management …

jp (code pays fourni par la source)

Additional file 1 of Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Supplementary Material 1.

jp (code pays fourni par la source)

Additional file 1 of Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Supplementary Material 1.

jp (code pays fourni par la source)

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Abstract Background Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the …

jp (code pays fourni par la source)

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Abstract Background Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the …

jp (code pays fourni par la source)